AACR logo

More articles from Research Articles: Therapeutics, Targets, and Development

MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib
Roland Houben, Heike Voigt, Christiane Noelke, Valeska Hofmeister, Juergen C. Becker, David Schrama

Molecular Cancer Therapeutics Feb 2009, 8 (2) 433-440; DOI: 10.1158/1535-7163.MCT-08-1051
Interruption of RNA processing machinery by a small compound, 1-[(4-chlorophenyl)methyl]-1H-indole-3-carboxaldehyde (oncrasin-1)
Wei Guo, Shuhong Wu, Li Wang, Rui-yu Wang, Xiaoli Wei, Jinsong Liu, Bingliang Fang

Molecular Cancer Therapeutics Feb 2009, 8 (2) 441-448; DOI: 10.1158/1535-7163.MCT-08-0839
Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors
Claudia Forni, Mario Minuzzo, Emanuela Virdis, Elena Tamborini, Matteo Simone, Michele Tavecchio, Eugenio Erba, Federica Grosso, Alessandro Gronchi, Pierre Aman, Paolo Casali, Maurizio D'Incalci, Silvana Pilotti, Roberto Mantovani

Molecular Cancer Therapeutics Feb 2009, 8 (2) 449-457; DOI: 10.1158/1535-7163.MCT-08-0848
Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitors
Xueming Xiao, Li Ning, Herbert Chen

Molecular Cancer Therapeutics Feb 2009, 8 (2) 350-356; DOI: 10.1158/1535-7163.MCT-08-0585
WIF1, a Wnt pathway inhibitor, regulates SKP2 and c-myc expression leading to G₁ arrest and growth inhibition of human invasive urinary bladder cancer cells
Yaxiong Tang, Anne R. Simoneau, Wu-xiang Liao, Guo Yi, Christopher Hope, Feng Liu, Shunqiang Li, Jun Xie, Randall F. Holcombe, Frances A. Jurnak, Dan Mercola, Bang H. Hoang, Xiaolin Zi

Molecular Cancer Therapeutics Feb 2009, 8 (2) 458-468; DOI: 10.1158/1535-7163.MCT-08-0885
Inhibition of cervical cancer cell growth by human papillomavirus virus–like particles packaged with human papillomavirus oncoprotein short hairpin RNAs
Latifa Bousarghin, Antoine Touze, Guillaume Gaud, Sophie Iochmann, Eva Alvarez, Pascale Reverdiau, Julien Gaitan, Marie-Lise Jourdan, Pierre-Yves Sizaret, Pierre L. Coursaget

Molecular Cancer Therapeutics Feb 2009, 8 (2) 357-365; DOI: 10.1158/1535-7163.MCT-08-0626
Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy
Young H. Kim, Beom K. Choi, Ho S. Oh, Woo J. Kang, Robert S. Mittler, Byoung S. Kwon

Molecular Cancer Therapeutics Feb 2009, 8 (2) 469-478; DOI: 10.1158/1535-7163.MCT-08-0993
Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells
Philipp Baumann, Sonja Mandl-Weber, Andreas Völkl, Christian Adam, Irmgard Bumeder, Fuat Oduncu, Ralf Schmidmaier

Molecular Cancer Therapeutics Feb 2009, 8 (2) 366-375; DOI: 10.1158/1535-7163.MCT-08-0664
Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy
Yunqing Li, Fadila Guessous, Charles DiPierro, Ying Zhang, Tucker Mudrick, Lauren Fuller, Elizabeth Johnson, Lukasz Marcinkiewicz, Matthew Engelhardt, Benjamin Kefas, David Schiff, Jin Kim, Roger Abounader

Molecular Cancer Therapeutics Feb 2009, 8 (2) 376-385; DOI: 10.1158/1535-7163.MCT-08-0627
Inhibition of Akt inhibits growth of glioblastoma and glioblastoma stem-like cells
Gary L. Gallia, Betty M. Tyler, Christine L. Hann, I-Mei Siu, Vincent L. Giranda, Angelo L. Vescovi, Henry Brem, Gregory J. Riggins

Molecular Cancer Therapeutics Feb 2009, 8 (2) 386-393; DOI: 10.1158/1535-7163.MCT-08-0680

Main menu

User menu

Search

More articles from Research Articles: Therapeutics, Targets, and Development

Pages

Articles

Info for

About MCT